Clinical Pharmacology: Advances and Applications, 2025:17 29–47
Preferred product characteristics and clinical development considerations
Tropical Medicine and Health (2023) 51:29
El Plan de acción regional sobre inmunización para las Américas (RIAP) constituye un paso fundamental para consolidar los avances alcanzados y proporciona una visión clara para enfrentar los desafíos actuales y futuros, con el objetivo de alcanzar las metas establecidas para el año 2030. Este ...plan es esencial para fortalecer los sistemas de salud, mejorar el acceso a la vacunación y optimizar la coordinación entre las partes interesadas, de manera de asegurar que todos los sectores de la población tengan la oportunidad de beneficiarse de programas de inmunización resilientes, eficaces y equitativos a lo largo del curso de vida. Diseñado en el marco de la política sobre Revitalizar la inmunización como un bien de salud pública para la salud universal y en consonancia con la Agenda de Inmunización 2030, en este plan se integran las prioridades definidas por los países y territorios, con indicadores que abordan seis líneas de acción: gobernanza, seguimiento, integración, comunicación, recursos humanos y toma de decisiones basada en la evidencia. Este enfoque integral e inclusivo reafirma el compromiso con el logro de la cobertura universal de salud y de los Objetivos de Desarrollo Sostenible. De cara al futuro, es esencial mantener un compromiso sólido a todos los niveles y adaptar las estrategias a los cambios que enfrentan los países y territorios, a fin de avanzar de manera eficaz en los esfuerzos de inmunización mediante mejores prácticas y enfoques innovadores. Se invita a todas las partes interesadas a unirse a este esfuerzo colectivo para garantizar la inmunización como un bien público y proteger a la población contra las enfermedades prevenibles por vacunación.
more
The Operational guide: use of referral laboratories for the analysis of foodborne hazards in the Pacific aims to strengthen the food analysis capacity of Pacific Island countries and areas by identifying national and reference laboratories capable of testing for priority foodborne hazards. The Pacif...ic Island countries and areas are often vulnerable to food safety incidents and emergencies due to their geographical distribution and dependence on food imports. The guide outlines key considerations for selecting referral laboratories and submitting samples to them, enabling continuous improvement of food safety systems and providing safe food for all. The target audiences are health and food safety authorities.
more
The prevalence of chronic non-communicable diseases such as diabetes, cardiovascular diseases and cancers has been on the increase in Kenya in the recent past. This has been occasioned by changes in social and demographic situation in the country. The life expectancy... in the country is improving, while the country is developing at a rapid pace. This has resulted in people living more years and at the time adopting lifestyles that have negative impacts on their health. This increase in diabetes and other non-communicable diseases has given rise to a double burden of communicable and non-communicable diseases in Kenya
more
The Lancet Regional Health - Americas 2024;36: 100821 https://doi.org/10.1016/j.lana.2024.100821
This first edition of our national neonatal care clinical guidelines is an initiative that aims to ensure that all the neonates in the Kingdom of Eswatini are offered standard, best quality of care and the best possible start in life. The guidelines have been formulated from various global sources a...nd tailored to the needs and health practises of the country. They are designed to serve as a guide to all healthcare providers in the country to provide standardized quality neonatal care.
more
Paraguay muestra avances en el compromiso asumido, de avanzar hacia la Salud Uni¬versal. La experiencia ha demostrado que el proceso puede acelerarse cuando existe un fuerte involucramiento social. En este marco se realizó un llamado a los líderes del MSPYBS, la sociedad civil y público en gener...al para lograr un sólido compromiso con las acciones que nos permitan avan¬zar hacia la salud para todos y todas en ámbitos específicos. El propósito fue el de abrir un espacio de diálogo que genere propuestas concretas para sentar las bases de un sistema de Salud Universal. En este marco se realizó un llamado a los líderes del MSPYBS, la sociedad civil y público en general para lograr un sólido compromiso con las acciones que nos permitan avan¬zar hacia la salud para todos y todas en ámbitos específicos. El propósito fue el de abrir un espacio de diálogo que genere propuestas concretas para sentar las bases de un sistema de Salud Universal.
more
Last updated Friday 20 March
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
SODIS manual - updated version
The SODIS manual contains detailed information about technical and promotional aspects of the SODIS method.
Former version also available in French, Portuguese, Spanish, Uzbek, Russian
Essential Medicines are those that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy, safety and comparative cost-effectiveness. This edition of the Essential Medicines List (EML) 2017 for Ghana has been deriv...ed from its companion Standard Treatment Guidelines 2017 to ensure harmony in treatment, procurement and re-imbursements. The medicines listed have been coded according to the Health Commodity
Codes Catalogue of the Ministry of Health (2008) and their levels of use, based on the type of health facility, including midwifery practice, have been indicated.
more
A guide for civil society
Accessed: 30.01.2020
Indonesian Prevention Guidelines on HIV and AIDS